Delivery Order SPE2DR25D1100-SPE2DR26FCL3B
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) under a firm fixed-price contract valued at $4,712.76, with completion targeted for September 10, 2025. This non-set-aside award represents a competitive procurement of pharmaceutical products to support federal healthcare needs. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical supplier within the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,288.86. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by October 20, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Envarsus XR 0.75 mg tablets (30-count) with a ceiling value of $2,339.52. This delivery order represents a competitive, firm fixed-price procurement with no set-aside designation and is scheduled for ultimate completion by September 17, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 4 mg tablets in a quantity of 100 units, with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for ultimate completion by October 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by October 7, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement, reflecting AmerisourceBergen's established capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) valued at $1,035.60. This non-competitive delivery order, which will be completed by June 24, 2025, represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a $2,263.75 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Envarsus XR 1 mg tablets in quantities of 100 units. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by November 12, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Envarsus XR 1 mg tablets (100-count) with a ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 21, 2025. This delivery order is a child contract...
- The Defense Logistics Agency awarded a $3,423.90 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages). This firm fixed price, non-set-aside contract is scheduled for completion by September 10, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs through the agency's established...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on March 18, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for completion by April 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis, reflecting AmerisourceBergen's capability to meet federal procurement standards...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCL3BDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $3,608.26. This firm fixed price delivery order, which is scheduled for completion by November 20, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor and critical vendor for federal medical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive global pharmaceutical support vehicle running through December 2026. As a prime contractor on this IDC, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The company's consistent receipt of competitively awarded, non-set-aside contracts across multiple therapeutic domains demonstrates its proven capability to meet federal medical supply requirements efficiently and cost-effectively.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 10/29/25 |